title: Imaging chemical exchange saturation transfer (CEST) effects following tumor-selective acidification using lonidamine.
abstract: Increased lactate production through glycolysis in aerobic conditions is a hallmark of cancer. Some anticancer drugs have been designed to exploit elevated glycolysis in cancer cells. For example, lonidamine (LND) inhibits lactate transport, leading to intracellular acidification in cancer cells. Chemical exchange saturation transfer (CEST) is a novel MRI contrast mechanism that is dependent on intracellular pH. Amine and amide concentration-independent detection (AACID) and apparent amide proton transfer (APT*) represent two recently developed CEST contrast parameters that are sensitive to pH. The goal of this study was to compare the sensitivity of AACID and APT* for the detection of tumor-selective acidification after LND injection. Using a 9.4-T MRI scanner, CEST data were acquired in mice approximately 14 days after the implantation of 10(5) U87 human glioblastoma multiforme (GBM) cells in the brain, before and after the administration of LND (dose, 50 or 100 mg/kg). Significant dose-dependent LND-induced changes in the measured CEST parameters were detected in brain regions spatially correlated with implanted tumors. Importantly, no changes were observed in T1- and T2-weighted images acquired before and after LND treatment. The AACID and APT* contrast measured before and after LND injection exhibited similar pH sensitivity. Interestingly, LND-induced contrast maps showed increased heterogeneity compared with pre-injection CEST maps. These results demonstrate that CEST contrast changes after the administration of LND could help to localize brain cancer and monitor tumor response to chemotherapy within 1 h of treatment. The LND CEST experiment uses an anticancer drug to induce a metabolic change detectable by endogenous MRI contrast, and therefore represents a unique cancer detection paradigm which differs from other current molecular imaging techniques that require the injection of an imaging contrast agent or tracer.
authors: Department of Medical Biophysics, University of Western Ontario, London, ON, Canada.
authors: Nevin
authors: N
authors: McVicar
authors: Alex X
authors: AX
authors: Li
authors: Susan O
authors: SO
authors: Meakin
authors: Robert
authors: R
authors: Bartha
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000737:chemistry* / Q000175:diagnosis*; D003287:Contrast Media; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007090:Image Interpretation, Computer-Assisted / Q000379:methods; D007191:Indazoles / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D051379:Mice; D008819:Mice, Nude; D057054:Molecular Imaging / Q000379:methods*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D003287:Contrast Media; D007191:Indazoles; C016371:lonidamine
keywords: Animal model study < Cancer < Applications; Cellular and molecular cancer imaging < Cellular and molecular imaging < Applications; Chemical exchange saturation transfer < Endogenous Contrast Methods < Methods and Engineering; Magnetization transfer (MT) < Endogenous Contrast Methods < Methods and Engineering